All In Biotech

NDA 013422 · Harrow Eye

Maxidex

Dexamethasone · Ophthalmic · Corticosteroid

Last checked: Nov 20, 2026Latest source record: Dec 10, 2021 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1962

Jun 20, 1962

Approved uses

1

Original approval plus efficacy supplements

Registered trials

4,222

936 Phase 3, 495 recruiting

FAERS reports

296,229

250,852 serious, 48,093 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect May 5, 2025.

INDICATIONS AND USAGE Steroid responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe, such as allergic conjunctivitis, acne rosacea, superficial punctate keratitis, herpes zoster keratitis, iritis, cyclitis, selected infective conjunctivitides when the inherent hazard of steroid use is accepted to obtain an advisable diminution in edema and inflammation; corneal injury from chemical, radiation, or thermal burns, or penetration of foreign bodies.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Jun 20, 1962 Original approval · Type 3 - New Dosage Form
1 products under this application
  • MAXIDEX · DEXAMETHASONE 0.1% · SUSPENSION/DROPS, OPHTHALMIC · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Dexamethasone" as an intervention, any sponsor and status, largest first.

All 4,222 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • off label use22,720
  • fatigue17,522
  • diarrhoea17,329
  • plasma cell myeloma14,404
  • nausea14,227
  • pneumonia13,830
  • death13,374
  • drug ineffective13,237
  • neutropenia11,785
  • pyrexia11,130
  • thrombocytopenia10,776
  • dyspnoea10,408

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20041,568
20052,141
20061,107
2007891
20081,328
20091,942
20103,611
20115,411
20126,731
20136,747
20148,373
201517,419
201615,878
201717,891
201823,348
201923,301
202025,281
202128,980
202227,311
202324,185
202421,496
202518,480
202612,807

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Maxidex (Dexamethasone)

2024 spending

$99K

Beneficiaries

657

1,040 claims

Per beneficiary

$151

$16.75 per unit

View as table
YearSpending
2020$0
2021$0
2022$12,927
2023$100,482
2024$99,051

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 7,424 on PubMed

Sponsor: Harrow Eye

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.